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disributions. RESULTS: In the base case, NA-E was found to be
the most cost-effective alternative. NA-E cost 321UAH (1
USD = 5.05 UAH) compared to 930UAH for D-E, 1319UAH for
transdermal N-E to prevent a single pregnancy per patient per
year. Monte –Carlo sensivity analysis conﬁrmed these ﬁndings.
CONCLUSION: The cost-effectiveness ratio NA-E dominated
all contraceptive strategies.These direct medical costs, in turn,
were driven by differential compliance that favored NA-E.
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OBJECTIVE: To conduct a cost-effectiveness analysis of contra-
ceptives available in the United States from a payer’s perspective.
METHODS: A Markov model was constructed to simulate
method failure (deﬁned as ectopic pregnancy, abortion, or full-
term birth) and costs among 17 contraceptive methods over a
5-year period: vasectomy, tubal ligation, injectable, implant,
copper-T IUD, LNG-20 IUS, oral contraceptives, diaphragm,
male condom, female condom, spermicides, sponge, patch,
NuvaRing, withdrawal, periodic abstinence and no method. In
each yearly cycle, subjects transition to “continue contracep-
tion”, “method failure” or “plan disenrollment”. Subjects
remain on the method for the model duration after method
failure or adverse effect. We assumed that 60% of unintended
births are mistimed and would occur two years later. Failure rate,
adverse event rates, and resource utilization were derived from
comprehensive literature review and supplemented with expert
opinion. Unit costs were obtained from published fee schedules
and drug prices. Future costs and effectiveness were discounted at
3%/year. Sensitivity analyses were performed on cost and failure
rates. RESULTS: Any contraceptive method is superior to “no
method” in terms of costs and success rate. The three least
expensive methods were copper-T IUD ($645), vasectomy ($713)
and LNG-20 IUS ($930). The most effective methods (99.6%
success rate) were vasectomy, implant, tubal ligation, LNG-20
IUS and copper-T IUD. Results were sensitive to variations in
cost of contraception method, cost of unintended pregnancy and
plan disenrollment rates. Moreover, with a longer time horizon,
methods with high initial costs (ie, copper-T IUD, vasectomy
and LNG-20 IUS) and high effectiveness rates become more
cost-effective. CONCLUSION: Copper-T IUD, vasectomy and
LNG-20 IUS are among the most effective methods currently
available in the US market. This analysis demonstrates that dif-
ferences in efﬁcacy, method costs, cost of unintended pregnancies
and time horizon are inﬂuential factors that determine the overall
value of a contraception method.
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OBJECTIVE: To estimate the cost-effectiveness of screening
for vasa previa at 18–20 weeks gestation. Several screening
strategies were considered for singleton and twin pregnancies.
METHODS: We constructed a decision-analytic model to esti-
mate the incremental costs and beneﬁts associated with screening
for vasa previa at 18–20 weeks gestation. We compared the
status quo of not screening to scenarios in which all singleton and
twin pregnancies were screened using transvaginal color Doppler
ultrasound. We also considered strategies in which only high-risk
pregnancies were screened. Costs were collected primarily from
the London Health Sciences Centre case costing initiative and
from the OHIP Schedule of Beneﬁts for Physicians. Other data
estimates were obtained from published sources and expert
opinion. Health beneﬁts were measured in life-years (LY) gained.
Costs and health beneﬁts were estimated for a cohort of preg-
nancies in Ontario in 1 year. RESULTS: Compared to not screen-
ing, screening all twin pregnancies for vasa previa has an
incremental cost effectiveness ratio (ICER) of less than $10,000
per LY gained. Among all risk factors in singleton pregnancies,
velementous cord insertion is the strongest predictor of vasa
previa. Identifying and screening pregnancies affected by vela-
mentous cord insertion has an ICER of less than $10,000 per LY
gained compared to not screening. Compared to screening only
pregnancies identiﬁed as having a velamentous cord insertion,
screening all pregnancies has an ICER of approximately $75,000
per LY-gained. Compared to screening for vasa previa in
pregnancies identiﬁed as having any high risk indicator, routine
screening of all pregnancies has an ICER of over $100,000 per
LY gained. CONCLUSION: A strategy of screening all twin and
all high-risk singleton pregnancies for vasa previa has a very low
incremental cost effectiveness ratio and should be considered for
adoption. However, routine screening of all pregnancies is not
likely to be cost effective.
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OBJECTIVE: Prophylactic therapy with palivizumab, a human-
ized monoclonal antibody, reduces the number of respiratory
syncytial virus (RSV)-related hospitalizations in preterm infants,
including those in the 32 to 35 weeks gestational age (GA)
subgroup. The cost-effectiveness of this therapy in Canada is
unknown. To evaluate the cost-effectiveness of palivizumab as
respiratory syncytial virus prophylaxis in premature infants born
at 32 to 35 weeks GA, from both the payer (base-case) and
societal perspectives. METHODS: A decision analytic model was
designed to compare costs and beneﬁts of prophylaxis in this
subgroup of premature infants. Sensitivity analyses were per-
formed to ascertain the robustness of the model by varying
mortality, health utilities, discount rates and administration
costs. SETTING: Canadian publicly funded health care system
(base-case analysis). PARTICIPANTS: Canadian infants born at
32 to 35 weeks gestation without chronic lung disease. INTER-
VENTIONS: Palivizumab prophylaxis versus no prophylaxis.
MAIN OUTCOME MEASURES: Expected costs and incremen-
tal cost-effectiveness ratio expressed as cost per quality-adjusted
life-year (QALY) gained using $CAN 2006. RESULTS: The
expected costs were higher for palivizumab prophylaxis as com-
pared with no prophylaxis. The incremental cost-effectiveness
ratio for the base-case scenario was $16,605 per QALY after
discounting, which is considered cost-effective. Sensitivity analy-
ses showed the model was robust through reasonable estimates
of key variables. Sub-analyses that varied risk of RSV based on
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